前列地尔联合氯沙坦钾治疗糖尿病肾病的临床效果观察  

Analysis on clinical efficacy of alprostadil and losartan potassium in the treatment of diabetic nephropathy

作　　者：高志光[1] 张波[1] 李彦生[1] 

机构地区：[1]广东省佛山市第二人民医院肾内科,广东佛山528000

出　　处：《中国当代医药》2015年第18期118-120,共3页China Modern Medicine

摘　　要：目的 探讨前列地尔联合氯沙坦钾治疗糖尿病肾病的临床疗效。方法 回顾性分析2012年1月-2014年8月本院收治的110例糖尿病肾病患者,分为观察组和对照组,各55例,观察组给予前列地尔联合氯沙坦钾治疗,对照组给予常规胰岛素降糖、降压治疗,综合比较两组患者治疗总有效率、治疗前后24 h尿蛋白、尿素氮（BUN）、内生肌酐清除率（CCr）的变化及不良反应发生率。结果 观察组治疗总有效率为90.9%,高于对照组的76.4%（P〈0.05）;治疗2周后,观察组24 h尿蛋白及BUN明显下降,CCr明显升高,改善程度优于对照组（P〈0.05）;两组患者均未见明显不良反应、出血倾向（P〉0.05）。结论 前列地尔联合氯沙坦钾治疗糖尿病肾病效果确切,可明显缓解患者的临床症状,改善肾功能,未见明显不良反应,值得临床推广应用。Objective To investigate the clinical effects of alprostadil combined with losartan potassium in the treatment of diabetic nephropathy. Methods 110 cases with diabetic nephropathy in our hospital from January 2012 to August 2014 were analyzed retrospectively,randomly divided into observation group and control group,with 55 cases in each group.Observation group were treated with alprostadil combined with losartan potassium.Control group were treated with conventional insulin antidiabetic,antihypertensive therapy.The total effective rate,24 h urine protein,blood urea nitrogen（BUN）,creatinine clearance（CCr） before and after treatment and adverse reactions rate between two groups was compared respectively. Results The total effective rate of observation group was 90.9%,which was higher than 76.4% of control group（P〈0.05）.After two weeks of treatment,the 24 h urine protein and BUN of observation group was decreased,CCr was significantly increased,and the degree of improvement was better than control group（P〈0.05）.There were no significant adverse reactions and bleeding tendency between two groups（P〉0.05）. Conclusion Alprostadil combined with losartan potassium in the treatment of diabetic nephropathy has exact effect.It can effectively improve the clinical symptoms and renal function without significant adverse reactions.It is worthy of clinical promotion and application.

关 键 词：前列地尔 氯沙坦钾 糖尿病肾病 临床疗效 

分 类 号：R587.2[医药卫生—内分泌]